AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
40.67
-0.73 (-1.76%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close41.40
Open39.95
Bid37.00 x 1400
Ask0.00 x 2200
Day's Range39.94 - 40.71
52 Week Range31.99 - 41.78
Volume7,069,209
Avg. Volume4,245,535
Market Cap99.069B
Beta (3Y Monthly)0.64
PE Ratio (TTM)38.55
EPS (TTM)1.05
Earnings DateN/A
Forward Dividend & Yield1.40 (3.42%)
Ex-Dividend Date2018-08-09
1y Target Est42.66
Trade prices are not sourced from all markets
  • Stocks Slide At Open; This Dow Jones Name Bucks Chip Sell Off
    Investor's Business Daily2 days ago

    Stocks Slide At Open; This Dow Jones Name Bucks Chip Sell Off

    Early losses in chip stocks and retail names sent stocks to a weak open Friday, but Viacom rose on earnings, and PG&E received some relief.

  • Is AstraZeneca PLC (LON:AZN) Excessively Paying Its CEO?
    Simply Wall St.2 days ago

    Is AstraZeneca PLC (LON:AZN) Excessively Paying Its CEO?

    Pascal Soriot became the CEO of AstraZeneca PLC (LON:AZN) in 2012. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that the Read More...

  • Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
    Zacks2 days ago

    Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings

    FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.

  • AstraZeneca Shows It Can Still Take Some Knocks
    Bloomberg2 days ago

    AstraZeneca Shows It Can Still Take Some Knocks

    On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.

  • Bloomberg3 days ago

    AstraZeneca’s Lung Cancer Trial Fails to Meet Main Goal

    The cocktail of Imfinzi and tremelimumab didn’t improve patients’ overall survival in non-small-cell lung cancer compared with standard chemotherapy alone, the company said Friday in a statement. The results didn’t meet statistical significance, and the data support further analysis, Astra said. Imfinzi is one of a number of new drugs, along with Lynparza for cancer and Farxiga for diabetes, that Astra is looking to for growth in the coming years as it pares away fading blockbusters.

  • Financial Times3 days ago

    [$$] AstraZeneca Mystic lung cancer trial fails to deliver results

    lung cancer treatment has confirmed the treatment fails to deliver the improvements to survival rates that had been hoped for. AstraZeneca had hoped the medicine, whichis called Imfinzi, would eventually be adopted as a first line treatment for non-small cell lung cancer. when an earlier version of the study, known as Mystic, showed the treatment had failed to meet its “endpoints” for progression-free survival — the length of time for which people go without their cancer worsening — in previously-untreated patients with Stage IV of the cancer.

  • This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal
    Investor's Business Daily5 days ago

    This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal

    AstraZeneca stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to infant respiratory drug for $1.5 billion.

  • AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi
    Zacks4 days ago

    AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi

    AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio

  • Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
    Zacks4 days ago

    Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

    PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

  • AstraZeneca (AZN): Are Hedge Funds Right to be Bearish?
    Insider Monkey4 days ago

    AstraZeneca (AZN): Are Hedge Funds Right to be Bearish?

    Does AstraZeneca plc (ADR) (NYSE:AZN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and invest millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]

  • AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
    Zacks5 days ago

    AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

    AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.

  • $1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine
    American City Business Journals5 days ago

    $1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine

    AstraZeneca's deal to sell the U.S. rights to Synagis to a Swedish biopharmaceutical company is expected to be finalized early next year.

  • AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi
    Bloomberg6 days ago

    AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi

    Sobi, officially Swedish Orphan Biovitrum AB, also gained the right to share the U.S. profits and losses on a potential new medicine, which Astra is developing with Sanofi, that targets the same lung virus Synagis treats, the Cambridge, England-based company said in a statement. Chief Executive Officer Pascal Soriot has been paring back Astra’s portfolio, selling the rights to fading blockbusters such as Nexium for reflux as a new crop emerges, led by Imfinzi and other cancer drugs.

  • The Wall Street Journal6 days ago

    [$$] European Corporate Roundup

    AG said earnings fell sharply in the third quarter, in part as a result of a one-off gain booked in the prior year, while the number of glyphosate-related lawsuits it faces rose. Aftertax profit at the German chemical maker was 2.89 billion euros ($3.26 billion) compared with EUR3.88 billion a year earlier. DCC PLC said pretax profit in the first half of fiscal 2019 rose 17% and it continues to expect the full year to see more profit growth.

  • Reuters6 days ago

    Sobi buys rights to AstraZeneca infant drug for $1.5 bln upfront

    AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the treatment Synagis in the United States.

  • Reuters6 days ago

    AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront

    AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States. Sobi also gets the right to participate in AstraZeneca's share of U.S. profits and losses in a follow-on drug for respiratory syncytial virus, called MEDI8897, which AstraZeneca is developing with Sanofi, the companies said.

  • Business Wire6 days ago

    US FDA Accepts Regulatory Submission For LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review

    Approval would expand use of AstraZeneca and MSD’s LYNPARZA to patients in the 1st-line setting following platinum-based chemotherapy

  • Business Wire8 days ago

    FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

    Fewer MACE events observed with FARXIGA vs. placebo, but this finding did not reach statistical significance

  • Reuters8 days ago

    AstraZeneca's diabetes drug curbs heart failure, kidney risks

    The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. Diabetics are at increased risk of heart problems, making the CV profile of drugs to treat the condition an important focus for doctors and patients.

  • Financial Times9 days ago

    [$$] AstraZeneca diabetes drug cuts complications

    has markedly reduced the chances of diabetic patients being hospitalised with heart failure, a condition associated with type 2 diabetes. The findings, from a large clinical trial, represent a significant boost for the Anglo-Swedish drugmaker which is striving to meet ambitious revenue targets. Cardio-vascular complications are common in people who contract type 2 diabetes, which has become a major burden on health systems worldwide.

  • Assessing GW Pharmaceuticals’ Year-to-Date Performance
    Market Realist9 days ago

    Assessing GW Pharmaceuticals’ Year-to-Date Performance

    GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.

  • Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
    Zacks9 days ago

    Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

    Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb

    NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.

  • Financial Times10 days ago

    [$$] Opinion today: Europe’s plan for Donald Trump

    This article is from today’s FT Opinion email.  Sign up to receive a daily digest of the big issues straight to your inbox. Does Europe have a strategy for coping with Donald Trump? His “America First” ...

  • Investor's Business Daily10 days ago

    AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak

    AstraZeneca stock broke out Thursday after the pharma reported sales growth, claiming the quarter to be the beginning of continued growth.